Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Next Previous
Trial Profile

A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 24 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Safusidenib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 18 Mar 2026 Status changed from recruiting to completed.
  • 01 Oct 2025 Primary endpoint (Phase 0: Feasibility of Phase 0 study in patient population) has been met, according to results published in the Nature Medicine.
  • 01 Oct 2025 Results (n=10, data cut-off: 8 Nov 2024) assessing endpoints from the perioperative component of the study, to assess biological effects of mIDH1 inhibition in tumor and peri-tumoral brain,including safety till a median duration of 14 months, published in the Nature Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top